Net Income

MENA's streaming leader Anghami doubles its subscribers after its OSN+ merger, but a $37M loss raises questions about its high-stakes growth strategy.

Facing a Nasdaq delisting threat, China-based WF International has 180 days to revive its stock after a dramatic collapse since its April IPO.

INVO Fertility realigns its top brass, positioning a deal-making veteran to lead an aggressive clinic acquisition strategy in a booming market.

As 10x Genomics preps for its J.P. Morgan spotlight, investors seek a clear path to profit amid fierce competition and groundbreaking innovation.

Investors await Polaris's Q4 results on Jan. 27, seeking clarity on market share gains, tariff impacts, and the future of its Indian Motorcycle brand.

With CEO David Endicott set to present at the J.P. Morgan Healthcare Conference, all eyes are on Alcon's strategy for innovation and market growth.

As Axos sets to reveal its Q2 results, investors weigh strong growth forecasts against mounting concerns over margin pressure and a shifting economy.

Amid economic headwinds, the M&A advisor thrived by securing over 90 deals and promoting key partners, signaling strong momentum for healthcare sales in 2026.

Fresh off a successful IPO, Ceribell is set to showcase its revolutionary AI-powered EEG system, a device already changing outcomes in ICUs nationwide.

A strategic alliance surpassed its goals sevenfold, fueling small businesses, creating 1,200+ jobs, and offering a new blueprint for rural revitalization.

New Era Energy & Digital faces a major fraud lawsuit from New Mexico over abandoned oil wells, threatening its pivot to a high-tech data center future.

Customers face a 3% interim water rate hike in January as regulators review a plan that could see bills climb over 30% to fund infrastructure.

Peruvian financial giant Credicorp is buying Florida's Helm Bank, a strategic move to capture the lucrative cross-border wealth of Latin American clients.

The biopharma investment giant has now acquired 100% of the royalty stream for Roche's blockbuster SMA drug, a strategic move years in the making.

Just months after its IPO, Kandal M Venture is fighting to stay on Nasdaq. We explore the financial woes behind the stock's dramatic fall.

Riding a wave of record revenue and a favorable reimbursement outlook, iRhythm's upcoming JPM presentation is a key test for its 2026 growth strategy.

Veracyte prepares for the J.P. Morgan conference, where it will showcase its AI and genomic strategy amid strong financials and a competitive market.

Activist investor Milfam LLC elected its entire slate to Scully Royalty's board at a disputed meeting held outside a locked room, ousting management.

Facing stock pressure, Dot Ai bets on seasoned sales leader Delores Rochester to scale its enterprise business in the booming Asset Intelligence market.

As CooperCompanies heads to the J.P. Morgan conference, all eyes are on CEO Al White's strategic vision for its dual vision and women's health units.